{"id":2679,"date":"2019-09-01T12:00:00","date_gmt":"2019-09-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/pharmakotherapie-beim-fruehen-idiopathischen-parkinson-syndrom"},"modified":"2022-09-30T09:32:33","modified_gmt":"2022-09-30T07:32:33","slug":"pharmakotherapie-beim-fruehen-idiopathischen-parkinson-syndrom","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/pharmakotherapie-beim-fruehen-idiopathischen-parkinson-syndrom","title":{"rendered":"Pharmakotherapie beim fr\u00fchen idiopathischen Parkinson-Syndrom"},"content":{"rendered":"<p>Zusammenfassung: Zur Therapie des idiopathischen Parkinson-Syndroms (IPS) im fr\u00fchen Stadium stehen drei Wirkstoffgruppen zur Verf\u00fcgung. Bei geringen motorischen Einschr\u00e4nkungen sind die MAO-B-Hemmer Selegilin und Rasagilin zur initialen Monotherapie geeignet. Bei relevanten motorischen Symptomen sollte die Behandlung mit Levodopa oder einem Dopamin-Agonisten begonnen werden, ggf. in Kombination. Levodopa ist weiterhin als wirksamstes Arzneimittel der Goldstandard in [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Zur Therapie des idiopathischen Parkinson-Syndroms (IPS) im fr\u00fchen Stadium stehen drei Wirkstoffgruppen zur Verf\u00fcgung. Bei geringen motorischen Einschr\u00e4nkungen sind die MAO-B-Hemmer Selegilin und Rasagilin zur initialen Monotherapie geeignet. Bei relevanten motorischen Symptomen sollte die Behandlung mit Levodopa oder einem Dopamin-Agonisten begonnen werden, ggf. in Kombination. Levodopa ist weiterhin als wirksamstes Arzneimittel der Goldstandard in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[5272,5273,5275,629,5276,665,1438,1942,1941,1439,5274,1754,3186,376,2279,3230,1939],"class_list":["post-2679","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-digpd-studie","tag-elldopa-studie","tag-impulskontrollstoerungen","tag-l-dopa","tag-leap-studie","tag-levodopa","tag-m-parkinson","tag-mao-hemmer","tag-monoaminooxidase-hemmer","tag-parkinson-syndrom","tag-piribedil","tag-pramipexol","tag-rasagilin","tag-ropinirol","tag-rotigotin","tag-safinamid","tag-selegilin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2679"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2679\/revisions"}],"predecessor-version":[{"id":31417,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2679\/revisions\/31417"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}